Understanding treatment decisions for Hodgkin lymphoma: a qualitative study

References

• Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–198. doi:10.1200/EDBK_156686
   PubMedGoogle Scholar
• Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245–255. doi:10.1093/jnci/djy221
   PubMedGoogle Scholar
• Hodgkin Lymphoma (Version 1.2017). [cited 2017 Sep 22]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
   Google Scholar
• Ries L, Kosary C, Hankey B, et al. SEER cancer statistics review: 1973–1994. Besthesda (MD): National Cancer Institute; 1997. NIH publ no 97-2781997.
   Google Scholar
• SEER Cancer Statistics. [cited 2021 Dec 1]. Available from https://seer.cancer.gov/statfacts/html/hodg.html
   Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi:10.1056/NEJMoa1510093
   PubMed Web of Science ®Google Scholar
• Saldana J. The coding manual for qualitative researchers. Thousand Oaks (CA): SAGE Publications; 2021.
   Google Scholar
• Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10. doi:10.2307/2137284
   PubMed Web of Science ®Google Scholar
• Lederle M, Tempes J, Bitzer EM. Application of Andersen’s behavioural model of health services use: a scoping review with a focus on qualitative health services research. BMJ Open. 2021;11(5):e045018. doi:10.1136/bmjopen-2020-045018
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514. doi:10.1056/NEJM199811193392104
   PubMed Web of Science ®Google Scholar
• Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–3022. doi:10.1200/JCO.2018.79.0139
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Nelson J, Rodday AM, et al. Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin lymphoma who receive dose-intense chemotherapy. J Geriatr Oncol. 2021;12(8):1233–1239. doi:10.1016/j.jgo.2021.07.003
   PubMed Web of Science ®Google Scholar
• Brockelmann PJ, McMullen S, Wilson JB, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2019;184(2):202–214. doi:10.1111/bjh.15566
   PubMed Web of Science ®Google Scholar
• Khan N, Feliciano J, Muller K, et al. Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma. 2020;61(11):2630–2637. doi:10.1080/10428194.2020.1783443
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652. doi:10.1056/NEJMoa1000067
   PubMed Web of Science ®Google Scholar
• Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin’s disease. The EORTC lymphoma cooperative group. Eur J Cancer. 1992;28A(11):1847–1850. doi:10.1016/0959-8049(92)90018-w
   PubMedGoogle Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–2511. doi:10.1056/NEJMoa1505949
   PubMed Web of Science ®Google Scholar
• Dores GM, Curtis RE, Dalal NH, et al. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000–2016. J Clin Oncol. 2020;38(35):4149–4162. doi:10.1200/JCO.20.00264
   PubMed Web of Science ®Google Scholar
• ADCETRIS combination significantly improves overall survival in newly diagnosed patients with advanced Hodgkin lymphoma. News release.: Seagen Inc.; 2022.
   Google Scholar
• Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22:1369–1379.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894–1904. doi:10.1016/S0140-6736(21)01789-X
   PubMed Web of Science ®Google Scholar
• Dale W. Why is geriatric assessment so infrequently used in oncology practices? The ongoing issue of nonadherence to this standard of care for older adults with cancer. J Clin Oncol Oncol Pract. 2022;18(7):475–477. doi:10.1200/OP.22.00197
   PubMedGoogle Scholar
• Li D, Sun CL, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):e214158. doi:10.1001/jamaoncol.2021.4158
   PubMed Web of Science ®Google Scholar
• Dale W, Klepin HD, Williams GR, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023. doi:10.1200/JCO.23.00933
   Web of Science ®Google Scholar
• Hamid MS, Rutherford SC, Jang H, et al. Outcomes among classical Hodgkin lymphoma patients after an interim PET scan: a real-world experience. Clin Lymphoma Myeloma Leuk. 2022;22(7):e435–e442. doi:10.1016/j.clml.2021.12.012
   PubMed Web of Science ®Google Scholar
• Towle E. Demographics of the US oncology workforce. J Oncol Pract. 2016;12(2):99–99. doi:10.1200/JOP.2015.010124
   PubMed Web of Science ®Google Scholar